L. Herbi

发表

The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia

V. Leblond, H. Merle-Béral, V. Vieillard, 2015, Haematologica.

Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion

F. Davi, S. Choquet, K. Maloum, 2014, Leukemia.

CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLCγ1 Activation: Evidence from Mice and Humans

F. Davi, P. Karoyan, E. Chapiro, 2015, PLoS medicine.

Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1

P. Feugier, S. Leprêtre, F. Davi, 2017, Leukemia.

Thrombospondin-1 Mimetic Agonist Peptides Induce Selective Death in Tumor Cells: Design, Synthesis, and Structure-Activity Relationship Studies.

O. Lequin, P. Karoyan, H. Merle-Béral, 2016, Journal of medicinal chemistry.

Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom's Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab

P. Debré, V. Leblond, H. Merle-Béral, 2012 .

Homotrimerization Approach in the Design of Thrombospondin-1 Mimetic Peptides with Improved Potency in Triggering Regulated Cell Death of Cancer Cells.

O. Lequin, P. Karoyan, H. Merle-Béral, 2019, Journal of medicinal chemistry.

Bone marrow microenvironment in an in vitro model of Gaucher disease: consequences of glucocerebrosidase deficiency.

V. Vanneaux, J. Larghero, C. Chomienne, 2012, Stem cells and development.